Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
Background: The use of continuing antipsychotic medication is an established evidence-based strategy for preventing relapse in people with schizophrenia, but medication adherence is known to be suboptimal. Covert non-adherence can be eliminated by the use of long-acting injectable (LAI) formulations...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-02-01
|
| Series: | Therapeutic Advances in Psychopharmacology |
| Online Access: | https://doi.org/10.1177/20451253211072347 |
| _version_ | 1819277117675798528 |
|---|---|
| author | Carol Paton Chike I. Okocha Maxine X. Patel |
| author_facet | Carol Paton Chike I. Okocha Maxine X. Patel |
| author_sort | Carol Paton |
| collection | DOAJ |
| description | Background: The use of continuing antipsychotic medication is an established evidence-based strategy for preventing relapse in people with schizophrenia, but medication adherence is known to be suboptimal. Covert non-adherence can be eliminated by the use of long-acting injectable (LAI) formulations. We sought to (1) raise awareness among clinicians of the potential benefits of LAI antipsychotic formulations, (2) increase use of these formulations for the treatment of schizophrenia in routine clinical practice and thereby (3) reduce the number of relapses requiring hospitalisation in patients with schizophrenia under our care. Method: Educational initiatives, promotion of reflective practice and patient-specific reminders were used to prompt increased use of LAI antipsychotic medication for patients with schizophrenia. Data relating to the use of these medications and the number of acute admissions for schizophrenia spectrum disorders (F20-29, ICD-10) over time were extracted from existing clinical information systems. Results: Over the 3-year time frame of our local initiative, the use of LAI antipsychotic preparations increased by 11%, the number of acute admissions for schizophrenia/schizoaffective disorder (F20 and F25) decreased by 26% and the number of acute bed days occupied by patients with these diagnoses decreased by 8%. The number of admissions for other psychosis diagnoses (F21-24 and F28-29) did not show the same pattern of improvement. Conclusion: In our health care organisation, raising clinicians’ awareness of the evidence base relating to the potentially favourable benefit–risk balance for LAI antipsychotic medication compared with oral formulations resulted in more use of the former. There were accompanying reductions in acute admissions and occupied bed days for patients with schizophrenia. |
| first_indexed | 2024-12-23T23:51:01Z |
| format | Article |
| id | doaj.art-e32f1b755f5f4c81a353ed662e2c7a66 |
| institution | Directory Open Access Journal |
| issn | 2045-1261 |
| language | English |
| last_indexed | 2024-12-23T23:51:01Z |
| publishDate | 2022-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Psychopharmacology |
| spelling | doaj.art-e32f1b755f5f4c81a353ed662e2c7a662022-12-21T17:25:24ZengSAGE PublishingTherapeutic Advances in Psychopharmacology2045-12612022-02-011210.1177/20451253211072347Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?Carol PatonChike I. OkochaMaxine X. PatelBackground: The use of continuing antipsychotic medication is an established evidence-based strategy for preventing relapse in people with schizophrenia, but medication adherence is known to be suboptimal. Covert non-adherence can be eliminated by the use of long-acting injectable (LAI) formulations. We sought to (1) raise awareness among clinicians of the potential benefits of LAI antipsychotic formulations, (2) increase use of these formulations for the treatment of schizophrenia in routine clinical practice and thereby (3) reduce the number of relapses requiring hospitalisation in patients with schizophrenia under our care. Method: Educational initiatives, promotion of reflective practice and patient-specific reminders were used to prompt increased use of LAI antipsychotic medication for patients with schizophrenia. Data relating to the use of these medications and the number of acute admissions for schizophrenia spectrum disorders (F20-29, ICD-10) over time were extracted from existing clinical information systems. Results: Over the 3-year time frame of our local initiative, the use of LAI antipsychotic preparations increased by 11%, the number of acute admissions for schizophrenia/schizoaffective disorder (F20 and F25) decreased by 26% and the number of acute bed days occupied by patients with these diagnoses decreased by 8%. The number of admissions for other psychosis diagnoses (F21-24 and F28-29) did not show the same pattern of improvement. Conclusion: In our health care organisation, raising clinicians’ awareness of the evidence base relating to the potentially favourable benefit–risk balance for LAI antipsychotic medication compared with oral formulations resulted in more use of the former. There were accompanying reductions in acute admissions and occupied bed days for patients with schizophrenia.https://doi.org/10.1177/20451253211072347 |
| spellingShingle | Carol Paton Chike I. Okocha Maxine X. Patel Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? Therapeutic Advances in Psychopharmacology |
| title | Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? |
| title_full | Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? |
| title_fullStr | Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? |
| title_full_unstemmed | Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? |
| title_short | Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised? |
| title_sort | can the use of long acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised |
| url | https://doi.org/10.1177/20451253211072347 |
| work_keys_str_mv | AT carolpaton cantheuseoflongactinginjectableantipsychoticpreparationsbeincreasedinroutineclinicalpracticeandthebenefitsrealised AT chikeiokocha cantheuseoflongactinginjectableantipsychoticpreparationsbeincreasedinroutineclinicalpracticeandthebenefitsrealised AT maxinexpatel cantheuseoflongactinginjectableantipsychoticpreparationsbeincreasedinroutineclinicalpracticeandthebenefitsrealised |